** Gene therapy developer Regenxbio's RGNX.O shares rise 4.5% to $8.15
** Co reports interim early-stage data for its experimental gene therapy, RGX-202, for the treatment of Duchenne muscular dystrophy (DMD)
** DMD causes skeletal and heart muscle weakness that quickly worsens with time
** The interim data from two additional patients, including one aged 3 years, builds on the favorable safety and efficacy profile seen in ages 4 and older - RGNX
** Co says there were no serious adverse events
** Co plans to share further functional early-stage data in H1 2025
** Including session gains, RGNX has fallen 63% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。